Topical treatment of cutaneous lesions from AIDS-related Kaposi's sarcoma (KS).
Binds to and activates retinoid receptors, resulting in inhibition of KS cells. Therapeutic Effects: Decreased cutaneous lesions of KS.
Adverse Reactions/Side Effects Local: pain, pruritus, rash, edema, exfoliative, dermatitis, paresthesia.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Assess the area being treated to help document whether drug therapy is successful in reducing skin lesions.
Monitor any new or increased reactions at the site of application, including inflammation, irritation, burning, swelling, numbness, tingling, exfoliation, and rash. Report severe or prolonged skin reactions to the physician.
Absorption: Small amounts are absorbed.
Metabolism and Excretion: Some metabolism occurs.
TIME/ACTION PROFILE (response of KS lesions)
|ROUTE ||ONSET ||PEAK ||DURATION |
|topical ||2 wk ||4–14 wk ||unknown |
Contraindicated in: Hypersensitivity to retinoids; OB: Potential for birth defects; Lactation: Use breast milk alternative.
Use Cautiously in: Patients with childbearing potential; Pedi: Safety not established.
Drug-Drug: Do not use concurrently with insect-repellent products containing N,N-diethyl-m-toluamide (DEET). Alitretinoin increases DEET absorption.
Topical (Adults): Apply generous coating twice daily to KS lesions initially; application may be increased to 3–4 times daily.
Topical gel: 0.1% in 60-g tubes.